REG - Genus - Appointment of Joint Corporate Broker

GenusAnnouncement

02/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220802:nRSB4959Ua&default-theme=true

RNS Number : 4959U  Genus PLC  02 August 2022

 

 
2 August 2022

 

Genus plc

('Genus' or the 'Company')

 

Appointment of Joint Corporate Broker

 

Genus plc (LSE: GNS), a leading global animal genetics company, is pleased to
announce the appointment of HSBC Bank plc ("HSBC") as its Joint Corporate
Broker alongside Peel Hunt and Liberum, with immediate effect. The appointment
is in addition to HSBC's existing role as Financial Adviser.

 

For further information, please contact:

 Genus plc                                  Tel: 01256 345970
 Stephen Wilson, Chief Executive Officer
 Alison Henriksen, Chief Financial Officer

 

 HSBC Bank plc - Joint Broker and Financial Adviser  Tel: 020 7991 8888
 Adam Miller / James Hopton / Keith Welch


 Buchanan                                            Tel: 0207 466 5000
 Charles Ryland / Chris Lane / Sophie Wills

This announcement is available on the Genus website www.genusplc.com
(http://www.genusplc.com/)

 

About Genus

Genus creates advances to animal breeding and genetic improvement by applying
biotechnology and sells added value products for livestock farming and food
producers. Its technology is applicable across livestock species and is
currently commercialised by Genus in the dairy, beef and pork food production
sectors.

 

Genus' worldwide sales are made in over seventy-five countries under the
trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen,
embryos and breeding animals with superior genetics to those animals currently
in farms. Genus's customers' animals produce offspring with greater production
efficiency, and quality, and use these to supply the global dairy and meat
supply chains.

 

The Group's competitive edge has been created from the ownership and control
of proprietary lines of breeding animals, the biotechnology used to improve
them and its global supply chain, technical service and sales and distribution
network.

 

With headquarters in Basingstoke, United Kingdom, Genus companies operate in
over twenty-five countries on six continents, with research laboratories
located in Madison, Wisconsin, USA.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFEVTLILIIF